121 related articles for article (PubMed ID: 18519037)
1. AML1-ETO interacts with Sp1 and antagonizes Sp1 transactivity through RUNT domain.
Wei H; Liu X; Xiong X; Wang Y; Rao Q; Wang M; Wang J
FEBS Lett; 2008 Jun; 582(15):2167-72. PubMed ID: 18519037
[TBL] [Abstract][Full Text] [Related]
2. AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation.
Ibañez V; Sharma A; Buonamici S; Verma A; Kalakonda S; Wang J; Kadkol S; Saunthararajah Y
Cancer Res; 2004 Jul; 64(13):4547-54. PubMed ID: 15231665
[TBL] [Abstract][Full Text] [Related]
3. Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs.
Maiques-Diaz A; Chou FS; Wunderlich M; Gómez-López G; Jacinto FV; Rodriguez-Perales S; Larrayoz MJ; Calasanz MJ; Mulloy JC; Cigudosa JC; Alvarez S
Leukemia; 2012 Jun; 26(6):1329-37. PubMed ID: 22289984
[TBL] [Abstract][Full Text] [Related]
4. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
[TBL] [Abstract][Full Text] [Related]
5. The distal zinc finger domain of AML1/MDS1/EVI1 is an oligomerization domain involved in induction of hematopoietic differentiation defects in primary cells in vitro.
Senyuk V; Li D; Zakharov A; Mikhail FM; Nucifora G
Cancer Res; 2005 Sep; 65(17):7603-11. PubMed ID: 16140925
[TBL] [Abstract][Full Text] [Related]
6. Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells.
Nimer SD; Moore MA
Oncogene; 2004 May; 23(24):4249-54. PubMed ID: 15156180
[TBL] [Abstract][Full Text] [Related]
7. Erythroid inhibition by the leukemic fusion AML1-ETO is associated with impaired acetylation of the major erythroid transcription factor GATA-1.
Choi Y; Elagib KE; Delehanty LL; Goldfarb AN
Cancer Res; 2006 Mar; 66(6):2990-6. PubMed ID: 16540647
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a pluripotent preleukaemic stem cell line by expression of the AML1-ETO fusion protein in Notch1-immortalized HSCN1cl10 cells.
Delaney C; Bernstein ID
Br J Haematol; 2004 May; 125(3):353-7. PubMed ID: 15086416
[TBL] [Abstract][Full Text] [Related]
9. Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells.
Li X; Xu YB; Wang Q; Lu Y; Zheng Y; Wang YC; Lübbert M; Zhao KW; Chen GQ
J Cell Physiol; 2006 Sep; 208(3):594-601. PubMed ID: 16741927
[TBL] [Abstract][Full Text] [Related]
10. Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis.
Peterson LF; Lo MC; Okumura AJ; Zhang DE
Blood Cells Mol Dis; 2007; 39(3):321-8. PubMed ID: 17692541
[TBL] [Abstract][Full Text] [Related]
11. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
12. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation.
Balkhi MY; Christopeit M; Chen Y; Geletu M; Behre G
Exp Hematol; 2008 Nov; 36(11):1449-60. PubMed ID: 18687517
[TBL] [Abstract][Full Text] [Related]
13. Decreased intranuclear mobility of acute myeloid leukemia 1-containing fusion proteins is accompanied by reduced mobility and compartmentalization of core binding factor beta.
Qiu J; Wong J; Tweardy DJ; Dong S
Oncogene; 2006 Jun; 25(28):3982-93. PubMed ID: 16474840
[TBL] [Abstract][Full Text] [Related]
14. [The effects of AML1B and AML1/ETO on the transactivation of TSC genes.].
Xu ZF; Wang L; Wang Y; Wang M; Rao Q; Xing HY; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2009 Dec; 30(12):804-7. PubMed ID: 20193599
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of Bcl-2, CEBPA and p14(ARF) by the AML1-ETO oncoprotein contributing to growth arrest and differentiation block in the U937 cell line.
Zhuang WY; Cen JN; Zhao Y; Chen ZX
Oncol Rep; 2013 Jul; 30(1):185-92. PubMed ID: 23673926
[TBL] [Abstract][Full Text] [Related]
16. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity.
Liu Y; Cheney MD; Gaudet JJ; Chruszcz M; Lukasik SM; Sugiyama D; Lary J; Cole J; Dauter Z; Minor W; Speck NA; Bushweller JH
Cancer Cell; 2006 Apr; 9(4):249-60. PubMed ID: 16616331
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation.
de Guzman CG; Warren AJ; Zhang Z; Gartland L; Erickson P; Drabkin H; Hiebert SW; Klug CA
Mol Cell Biol; 2002 Aug; 22(15):5506-17. PubMed ID: 12101243
[TBL] [Abstract][Full Text] [Related]
18. ETO interacting proteins.
Hug BA; Lazar MA
Oncogene; 2004 May; 23(24):4270-4. PubMed ID: 15156183
[TBL] [Abstract][Full Text] [Related]
19. E protein silencing by the leukemogenic AML1-ETO fusion protein.
Zhang J; Kalkum M; Yamamura S; Chait BT; Roeder RG
Science; 2004 Aug; 305(5688):1286-9. PubMed ID: 15333839
[TBL] [Abstract][Full Text] [Related]
20. PIG7, transactivated by AML1, promotes apoptosis and differentiation of leukemia cells with AML1-ETO fusion gene.
Liu J; Xing H; Chen Y; Wang L; Wang D; Rao Q; Tang K; Tian Z; He K; Wang M; Wang J
Leukemia; 2012 Jan; 26(1):117-26. PubMed ID: 21836606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
